Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVXGA Intranasal COVID Vaccine in Healthy Adults
NCT05736835Phase 2Completed
- Sponsor
- CyanVac LLC
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CVXGA in coronavirus disease 2019 (COVID-19), sponsored by CyanVac LLC. Started Sep 2023; status: completed.
02
Drugs
CVXGA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05736835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736835.